AVITA Medical, Inc.
RCEL
$7.81
-$0.36-4.41%
| Weiss Ratings | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.01 | |||
| Price History | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -16.20% | |||
| 30-Day Total Return | -23.58% | |||
| 60-Day Total Return | -41.01% | |||
| 90-Day Total Return | -39.74% | |||
| Year to Date Total Return | -38.94% | |||
| 1-Year Total Return | -48.69% | |||
| 2-Year Total Return | -45.73% | |||
| 3-Year Total Return | -11.45% | |||
| 5-Year Total Return | -73.07% | |||
| 52-Week High % Change | -47.95% | |||
| 52-Week Low % Change | 8.79% | |||
| Price | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $15.70 | |||
| 52-Week Low Price | $7.51 | |||
| 52-Week Low Price (Date) | May 14, 2024 | |||
| 52-Week High Price (Date) | Apr 02, 2024 | |||
| Valuation | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 215.34M | |||
| Enterprise Value | 225.44M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.39 | |||
| Earnings Per Share Growth | 70.82% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.32 | |||
| Price/Book (Q) | 47.86 | |||
| Enterprise Value/Revenue (TTM) | 3.51 | |||
| Price | $7.81 | |||
| Enterprise Value/EBITDA (TTM) | -4.07 | |||
| Enterprise Value/EBIT | -3.99 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 26.15M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (661) 367-9170 | |||
| Address | 28159 Avenue Stanford Valencia, CA 91355 | |||
| Website | avitamedical.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -88.04% | |||
| Profit Margin | -96.25% | |||
| Management Effectiveness | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -36.96% | |||
| Return on Equity | -- | |||
| Income Statement | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 64.25M | |||
| Total Revenue (TTM) | 64.25M | |||
| Revenue Per Share | $2.46 | |||
| Gross Profit (TTM) | 55.16M | |||
| EBITDA (TTM) | -55.45M | |||
| EBIT (TTM) | -56.57M | |||
| Net Income (TTM) | -61.85M | |||
| Net Income Avl. to Common (TTM) | -61.85M | |||
| Total Revenue Growth (Q YOY) | 29.67% | |||
| Earnings Growth (Q YOY) | -64.03% | |||
| EPS Diluted (TTM) | -2.39 | |||
| EPS Diluted Growth (Q YOY) | -59.83% | |||
| Balance Sheet | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 35.89M | |||
| Cash Per Share (Q) | $1.37 | |||
| Total Current Assets (Q) | 57.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.50M | |||
| Current Ratio (Q) | 2.828 | |||
| Book Value Per Share (Q) | $0.17 | |||
| Total Assets (Q) | 79.71M | |||
| Total Current Liabilities (Q) | 20.16M | |||
| Total Debt (Q) | 45.99M | |||
| Total Liabilities (Q) | 75.21M | |||
| Total Common Equity (Q) | 4.50M | |||
| Cash Flow | RCEL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 37.36M | |||
| Cash from Financing (TTM) | 3.51M | |||
| Net Change in Cash (TTM) | -8.07M | |||
| Levered Free Cash Flow (TTM) | -161.38M | |||
| Cash from Operations (TTM) | -48.94M | |||
